AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00253747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
Study NCT04263974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: Exercises and recommendations, based on current scientific evidence, and delivered through the app for Smartphone called CareHand. The intervention protocol is based on strengthening and stretching recommendations for rheumatoid arthritis and osteoarthritis in hands, transferred to an application format through explanatory videos together with tools to improve the autonomy, motivation and adherence of the patient
Study NCT03844282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical assessment (SCAT5)
Description: The SCAT5 is a standardized tool for evaluating sports-related concussions designed for use by physicians and licensed healthcare professionals in patients aged 13 years and above. It is a ten minute paper-based assessment which includes immediate and office/off-field assessments. SCAT5 incorporates the Maddocks' questions, Glasgow Coma Scale (GCS), cervical spine assessment and symptom evaluation, in addition to cognitive and neurological screening.
Study NCT04263974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional approach provided by the Andalusian Public Health System in Primary Care settings. This approach consists of routine visits to the general practitioner specialist, and the delivery of an exercise sheet and recommendations. This general mobility and stretching worksheet contains detailed images, as well as a description of how to perform the exercises and the dose to be taken. While most exercises are intended for the wrist and hands, this sheet also includes basic exercises for the elbow joint.
Study NCT03844282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ImPACT
Description: ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) is a neurocognitive assessment administered online or using desktop software in a controlled environment. ImPACT has two components: baseline testing and post-injury testing, both of which are used to determine if a patient can safely return to sporting activity post-concussion.
Study NCT03844282 — intervention group
Intervention type: BEHAVIORAL
Intervention: CANTAB
Description: Originally developed at the University of Cambridge, the Cambridge Neuropsychological Test Automated Battery (CANTAB) platform includes highly sensitive, precise and objective measures of cognitive function, correlated to neural networks. These tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.~The CANTAB touchscreen battery (www.camcog.com) will be utilised to perform neuropsychological assessments within RESCUE-RACER, whose study-specific protocol may include assessments of: Spatial Working Memory (working memory and strategy), Reaction Time (processing and psychomotor speed), Paired Associated Learning and the Multi-Tasking Test.
Study NCT03844282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: I-PAS/Dx100
Description: I-PAS™ (now re-named Dx 100) is a portable, head-mounted, neural functional assessment tool. With its integrated clinical eye tracking and digital display, the FDA has cleared (K171884) fourteen tests and an unmatched list of variables for clinical use for a variety of conditions. This utility of this device will be investigated for motorsport-related concussion.
Study NCT03844282 — intervention group
Intervention type: BIOLOGICAL
Intervention: Saliva sample
Description: Micro RNA's (miRNA's) are easily measured in saliva and have proven to have both diagnostic and prognostic use in sports-related concussion across the adolescent and adult populations, with levels persisting for some weeks after the concussive event. RESCUE-RACER will collect saliva samples for analysis of biomarkers of concussion, which may include miRNA and other markers of injury.
Study NCT01289769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine 0.7 microgram per kilogram in saline 20 ml given within 10 minutes before intubation
Study NCT01289769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline 20 ml( the same volume as dexmedetomidine) giving within 10 minutes.
Study NCT03844282 — intervention group
Intervention type: OTHER
Intervention: fMRI
Description: RESCUE-RACER participants will be invited to complete a functional MRI scan, whose 90-minute protocol may include: multi-parametric mapping (MPM), susceptibility weighted imaging (SWI), diffusion weighted imaging (DWI), proton spectroscopy and functional MRI (fMRI) with blood oxygenation-level dependent contrast (BOLD), completed at 7T (Tesla), or 3T if this is not possible.
Study NCT01439308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SB-705498 placebo
Study NCT01439308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB-705498
Description: 12mg intranasal SB-705498
Study NCT01334658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification cataract surgery
Description: A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).
Study NCT00313716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human erythropoietin, rhEpo
Description: The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
Study NCT00423878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Switching medication to aripiprazole for schizophrenia for up to 6 months in study
Study NCT00313716 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study NCT00122382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
Study NCT01560676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HEALTH[e]TEEN
Description: 8 lessons over 6-8 weeks
Study NCT01560676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HEALTH[e]TEEN + CST
Description: 12 lessons over 6-8 weeks
Study NCT02979275 — intervention group
Intervention type: PROCEDURE
Intervention: Open heart surgery on cardiopulmonary bypass.
Description: Brain oximetry and tissue saturation will be measured during operation. NGAL, cystatin-C, and Acute Kidney Injury Network (AKIN) criteria of AKI will be assessed durin first post-op day.
Study NCT04260360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
Description: NanoDoce is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate docetaxel nanoparticles within a well-characterized particle-size distribution. Prior to administration, the NanoDoce powder in vial is suspended with a sterile solution of Polysorbate 80 (0.0075% - 0.0375% (w/w))/Ethanol (0.06% - 0.3% (w/w)) in 0.9% Sodium Chloride for injection.
Study NCT04754009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Sensitive Yoga + TAU
Description: Trauma-Sensitive Yoga is a movement-based approach that are used to integrate both mind and body, and promote body awareness and acceptance for those who have been exposed to traumatic events and currently experience trauma symptoms.
Study NCT04754009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chen Style Tai Chi + TAU
Description: Chen Style Practical Method tai chi is a martial art that is used as a form of self-defense and to maintain physical health and well-being.
Study NCT04754009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Consists of traditional talk therapy for mental health.
Study NCT00943007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stealth Station
Description: Neuronavigation based on preoperative MRI
Study NCT00943007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoleStar N20
Description: Intraoperative MRI guided surgery
Study NCT04780230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS active
Description: An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
Study NCT04780230 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS sham
Description: An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
Study NCT01061346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40% Fat Diet, 20% Fructose Beverage
Description: 40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
Study NCT01061346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% Glucose Beverage
Description: 40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
Study NCT01061346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% Glucose Beverage
Description: 20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein
Study NCT03814746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab (SEG101)
Description: Crizanlizumab was supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion.~IV.
Study NCT03814746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for infusion IV.
Study NCT05106101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-glutamine
Description: L-glutamine oral powder in 5 gram packet
Study NCT00122382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months
Study NCT00122382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24
Study NCT00662649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Description: Patients self-administered fingolimod 0.5 mg capsules orally once daily.
Study NCT00662649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Description: Patients self-administered fingolimod 1.25 mg capsules orally once daily.
Study NCT02485093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Septal ventricular pacing
Description: Ventricular pacing must be at least 90%, from the septum and with optimized AV delay
Study NCT02485093 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VIP
Description: Ventricular pacing must be less than 10%.
Study NCT02465398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fracture Shoulder Arthroplasty
Description: Implantation of the Anatomical Shoulder Fracture System
Study NCT02766114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carpal tunnel release through Mini Transverse Approach
Description: Carpal tunnel release through a transverse cosmetic small incision over the distal wrist crease.
Study NCT00578474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidex otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Study NCT00578474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacin otic solution
Description: 5 drops into the infected ear(s) twice daily (morning and evening) for 10 days
Study NCT00578474 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study NCT00578474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study NCT03367819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT01308476 — intervention group
Intervention type: PROCEDURE
Intervention: SMS reminder
Description: daily SMS in the SMS group to remind of treatment with tiotropium
Study NCT01308476 — intervention group
Intervention type: PROCEDURE
Intervention: control group
Description: no daily SMS to remind of treatment with tiotropium
Study NCT01334658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-bicarbonate-Ringer Lactate (GBRL)
Description: A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).
Study NCT01334658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balanced Salt Solution (BSS®)
Description: A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).
Study NCT02956226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabinoids - 99% pure cannabinoids mix
Description: 99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
Study NCT02956226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil and flavors solution.
Study NCT03367819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT02956226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabinoids - whole plant extract
Description: Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
Study NCT01974310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy & Intraocular gas fill
Study NCT01974310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy & Intraocular gas fill
Study NCT01974310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative face-down positioning
Study NCT03506165 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: oral hygiene instructions, periodontal debridement and removal of other etiologic factors
Study NCT03852446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod HCL (F2) tablets
Description: The doses will be ascending per cohort from 600 mg to 2400 mg
Study NCT03852446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod base formulation
Description: Single oral administration of 1200 mg
Study NCT03852446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The matching placebo doses will be ascending per cohort from 1 to 4 tablets
Study NCT03852446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod HCL (F2) tablets
Description: Single oral administration of 1200 mg
Study NCT03330873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable balloon uterine stent
Description: The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter
Study NCT03330873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: Foley catheter can partly separate the sides of uterus wall.
Study NCT00591773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
Study NCT00591773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
Study NCT00591773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
Study NCT01243957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: LY2216684: 18 mg po QD on Days 1, 2, and 3 and Days 25-27
Study NCT01243957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)
Study NCT01250470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01250470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51/Survivin Peptide Vaccine
Description: Given SC
Study NCT01250470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT02129803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow, 20 LPM (via Optiflow cannula)
Description: Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
Study NCT02129803 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low FLow, 5 LPM (via Optiflow cannula)
Description: standard humidified wall medical air.
Study NCT02455310 — intervention group
Intervention type: BEHAVIORAL
Intervention: Educational activities to improve dementia care
Description: The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.
Study NCT02462967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GR-MD-02
Description: GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3
Study NCT02462967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for GR-MD-02
Study NCT00577512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTPACE
Description: * Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7~* Thalidomide 200 mg by mouth (PO) Days 1-7~* Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)~* Adriamycin 15 mg/m2 Days 1-4~* Cyclophosphamide 600 mg/m2 Days 1-4~* Etoposide 60 mg/m2 Days 1-4
Study NCT02118909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat
Study NCT02118909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole